Drug Information

Drug General Information
Drug ID
D0D0YM
Former ID
DIB002566
Drug Name
Amosulalol
Synonyms
Lowgan; LY-137224; YM-09538
Drug Type
Small molecular drug
Indication Hypertension [ICD9: 401; ICD10:I10-I16] Approved [533886]
Company
Yamanouchi Pharmaceutical Co Ltd
Structure
Download
2D MOL

3D MOL
Formula
C18H25ClN2O5S
Canonical SMILES
S(=O)(=O)(c1cc(ccc1C)C(O)CNCCOc1c(OC)cccc1)N
PubChem Compound ID
123707
Target and Pathway
Target(s) Beta-3 adrenergic receptor Target Info Modulator [533886], [551871]
Alpha-2C adrenergic receptor Target Info Modulator [533886], [551871]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
Endocytosis
Salivary secretionhsa04022:cGMP-PKG signaling pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Beta3 adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
Reactome Adrenoceptors
G alpha (s) signalling eventsR-HSA-390696:Adrenoceptors
Adrenaline signalling through Alpha-2 adrenergic receptor
Adrenaline,noradrenaline inhibits insulin secretion
G alpha (i) signalling events
G alpha (z) signalling events
Surfactant metabolism
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signalingWP58:Monoamine GPCRs
Platelet Aggregation (Plug Formation)
Integration of energy metabolism
GPCR downstream signaling
References
Ref 533886Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
Ref 533886Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.